Literature DB >> 19995740

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.

D E Furst1, E C Keystone, R Fleischmann, P Mease, F C Breedveld, J S Smolen, J R Kalden, J Braun, B Bresnihan, G R Burmester, F De Benedetti, T Dörner, P Emery, A Gibofsky, A Kavanaugh, B Kirkham, M H Schiff, J Sieper, N Singer, P L C M Van Riel, M E Weinblatt, M H Weisman, K Winthrop.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19995740     DOI： 10.1136/ard.2009.123885

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  30 in total

1.  Rheumatoid arthritis: Guidelines for RA therapy-avoiding hamartia.

Authors:  Arthur Kavanaugh
Journal:  Nat Rev Rheumatol       Date:  2010-09       Impact factor: 20.543

Review 2.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

3.  Lupeol, a triterpenoid isolated from Calotropis gigantea latex ameliorates the primary and secondary complications of FCA induced adjuvant disease in experimental rats.

Authors:  Venkatesan Saratha; Sorimuthu Pillai Subramanian
Journal:  Inflammopharmacology       Date:  2011-10-16       Impact factor: 4.473

4.  The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy.

Authors:  Kevin L Winthrop; Roger Baxter; Liyan Liu; Bentson McFarland; Donald Austin; Cara Varley; LeAnn Radcliffe; Eric Suhler; Dongsoek Choi; Lisa J Herrinton
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-12-10       Impact factor: 2.890

5.  Tocilizumab: a novel humanized anti-interleukin 6 receptor antibody for the treatment of patients with rheumatoid arthritis.

Authors:  Rieke Alten
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-06       Impact factor: 5.346

Review 6.  Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.

Authors:  Jasvinder A Singh; Alomgir Hossain; Amy S Mudano; Elizabeth Tanjong Ghogomu; Maria E Suarez-Almazor; Rachelle Buchbinder; Lara J Maxwell; Peter Tugwell; George A Wells
Journal:  Cochrane Database Syst Rev       Date:  2017-05-08

7.  Patients' independence of a nurse for the administration of subcutaneous anti-TNF therapy: A phenomenographic study.

Authors:  Ingrid Larsson; Stefan Bergman; Bengt Fridlund; Barbro Arvidsson
Journal:  Int J Qual Stud Health Well-being       Date:  2010-06-30

8.  Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.

Authors:  Martin Rudwaleit; Filip Van den Bosch; Martina Kron; Sonja Kary; Hartmut Kupper
Journal:  Arthritis Res Ther       Date:  2010-06-16       Impact factor: 5.156

Review 9.  Rationale of using different biological therapies in rheumatoid arthritis.

Authors:  Matthias Geyer; Ulf Müller-Ladner
Journal:  Arthritis Res Ther       Date:  2010-08-24       Impact factor: 5.156

10.  [ASAS recommendations on the use of TNF inhibitors for patients with axial spondyloarthritis : evaluation of the 2010 update in the German-speaking area].

Authors:  U Kiltz; J Sieper; J Braun
Journal:  Z Rheumatol       Date:  2013-02       Impact factor: 1.372
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.